Cantor Fitzgerald Downgrades Jazz Pharmaceuticals (JAZZ) to Hold on Xyrem Risk

February 26, 2014 6:49 AM

Cantor Fitzgerald downgraded Jazz Pharmaceuticals (NASDAQ: JAZZ) from Buy to Hold with a price target of $182.00 (from $170.00), following ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found